sionate-use program and leading tuberculosis physicians have agreed that the overall strategy was appropriate 6 .
Nearly 45% (213/481) of patients in Otsuka's phase 2B trial of Deltyba received a 6-month treatment extension that amounted to compassionate use. In addition, Otsuka has also launched a phase 3 trial and completed randomization of 511 patients, about 340 of whom are receiving Deltyba (ClinicalTrials.gov; NCT01424670).
Finally, the article compares the number of patients treated through the compassionate-use program of Sirturo and Deltyba, but it fails to note that Sirturo was approved in the US in 2012, whereas Deltyba was only approved in the EU late in 2013 and is still not approved in the US. Everyone wants to ensure that patients with life-threatening drug-resistant tuberculosis gain access to these new therapeutic options as quickly as possible, but it must be done safely and in a controlled setting. Otsuka has made a huge contribution to global tuberculosis control in bringing this new drug forward. We cannot, and should not, risk compromising patient safety by rushing forward carelessly. There will be a time for vastly expanded access to this new agent, but that time is not now.
